MRK · CIK 310158
What Merck & Co., Inc. told the SEC could break it.
Merck's defining exposure is its reliance on a single product: Keytruda (with Keytruda Qlex) generated $31.68 billion of $65.0 billion in total 2025 sales — roughly 49% — a concentration made sharper by the franchise's approaching loss of exclusivity. The rest of its register reflects the pressures on a global pharma. It has significant research and manufacturing operations in China, including work with entities like WuXi AppTec, that geopolitical tension could disrupt, and it faces drug-pricing pressure on both sides: China's NRDL negotiations recently averaged about 60% price cuts for new entries, while U.S. states tighten pricing and rebate rules. It also self-insures substantially all of its product-liability risk, carrying no insurance for most product liabilities.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- Keytruda/Keytruda Qlex = $31.68B of $65.0B total sales (~49%)high
Merck's single largest product franchise, Keytruda/Keytruda Qlex, generated $31.68 billion of $65.0 billion total company sales in 2025 (~49%) — extreme single-product concentration, heightened by Keytruda's approaching loss of exclusivity.
“Total Sales $ 65,011 $ 64,168 $ 60,115 Pharmaceutical 58,142 57,400 53,583 Keytruda/Keytruda Qlex 31,680 29,482 25,011”
SEC filing →As of 2026
Geographic concentration
- China research/manufacturing operations and WuXi AppTec dependence; geopolitical disruptionmedium
Merck has significant research and manufacturing operations in China, including working with Chinese entities such as WuXi AppTec; increased geopolitical tensions disrupting China operations could materially affect product development, sales and results.
“the Company has significant research and manufacturing operations in China, including working with Chinese entities such as Wuxi Apptech Co., Ltd. If geopolitical tensions were to increase and disrupt the Company's operations in China, such disruption could result in a material adverse effect on the Company's product development, sales, business, cash f”
Litigation
- self-insured product liability (no insurance for most product liabilities)medium
Merck self-insures substantially all of its product-liability risk and carries no insurance for most product liabilities, having concluded commercial coverage's cost outweighs available benefits — leaving it fully exposed to product-liability litigation.
“With respect to product liability, the Company self-insures substantially all of its risk, as the availability of commercial insurance has become more restrictive. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.”
SEC filing →As of 2026
Regulatory & policy
- China NRDL price negotiations (~60% average price cuts) and U.S. state drug-pricing lawsmedium
Inclusion in China's National Reimbursement Drug List can require price negotiation — a recent NRDL averaged ~60% price reductions for new entries — while U.S. states increasingly impose drug price/cost-transparency and Medicaid rebate pressure.
“A new NRDL was recently completed in which new entries averaged approximately 60% price reductions.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
SELLAS Life Sciences Group, Inc.
“we entered into a Clinical Trial Collaboration and Supply Agreement with Merck (known as MSD outside the United States and Canada), to assess the efficacy and safety of GPS in combination with Merck's anti-PD-1 therapy pembrolizumab”
Cited →“Reblozyl is the subject of a global licensing agreement pursuant to which we pay tiered royalties to Merck ranging from 20% to 24% of net sales, which are included in Cost of products sold.”
Cited →“As of December 31, 2025, 2024 and 2023, we had collaboration agreements with Merck & Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), and others.”
Cited →“Upon passing $ 3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65 % for any revenues above the threshold for such calendar year. Reimbursements of R&D costs to or from Merck are recorded within Research and development expenses”
Cited →“We pay to Merck Sharpe & Dohme B.V. ("Merck") quarterly contingent consideration in the form of a perpetual, tiered royalty expressed as a percentage of Cortrophin Gel net sales.”
Cited →“Either we or MSD may terminate an MSD Agreement for a breach of the agreement, for patient safety, or due to regulatory authority objections or actions.”
Cited →
Its suppliers
Daiichi Sankyo Company, Limited
“Merck is responsible for 75 % of the first $ 2.0 billion of research and development expenses. Merck includes its share of development costs associated with the collaboration as part of Research and development expenses. Following regulatory approval, Daiichi Sankyo will generally record sales worldwide (Daiichi Sankyo will be the principal on sales transactions) and the companies will equally share expenses as well as profits worldwide except for Japan”
Cited →“The increase was primarily due to $34.0 million higher revenue from our licensing agreements with Merck entered into during the second and fourth quarters of 2025, and $3.3 million higher revenue from existing and legacy collaboration agreements.”
Cited →WuXi AppTec Co., Ltd.
“the Company has significant research and manufacturing operations in China, including working with Chinese entities such as Wuxi Apptech Co., Ltd. If geopolitical tensions were to increase and disrupt the Company's operations in China, such disruption could result in a material adverse effect on the Company's product development, sales, business”
Cited →Bayer AG
“Alliance revenue from the collaboration grew 13% in 2025 reflecting higher demand in Bayer's marketing territories. The Company expects alliance revenue will decline in 2026 reflecting the loss of market exclusivity for Adempas in the U.S. Revenue also includes sales of Adempas and Verquvo in Merck's marketi”
Cited →“On December 15, 2020, we and Merck Sharp & Dohme Corp. (Merck), entered into a research”
Cited →“Winrevair is the subject of a licensing agreement pursuant to which Merck pays a 22% royalty on net sales of Winrevair to BMS.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch